Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
Recent Articles
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG -
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
China-focused Tigermed staves off biopharma gloom
3347.HK 300347.SHE
